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Summary
Composite endpoints that combine multiple outcomes on different scales are common in clinical
trials, particularly in chronic conditions. In many of these cases, patients will have to cross a
predefined responder threshold in each of the outcomes to be classed as a responder overall. One
instance of this occurs in systemic lupus erythematosus (SLE), where the responder endpoint
combines two continuous, one ordinal and one binary measure. The overall binary responder
endpoint is typically analysed using logistic regression, resulting in a substantial loss of informa-
tion. We propose a latent variable model for the SLE endpoint, which assumes that the discrete
outcomes are manifestations of latent continuous measures and can proceed to jointly model the
components of the composite. We perform a simulation study and find the method to offer large
efficiency gains over the standard analysis. We find that the magnitude of the precision gains
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are highly dependent on which components are driving response. Bias is introduced when joint
normality assumptions are not satisfied, which we correct for using a bootstrap procedure. The
method is applied to the Phase IIb MUSE trial in patients with moderate to severe SLE. We
show that it estimates the treatment effect 2.5 times more precisely, offering a 60% reduction in
required sample size.
Key words: Latent variable models; Composite endpoints; Responder analysis; Systemic lupus erythe-
matosus
1. Introduction
Composite endpoints combine multiple outcomes in order to determine the effectiveness or ef-
ficacy of a treatment for a given disease. They are typically recommended when a disease is
complex or multi-system and meaningful improvement cannot be captured in a single outcome.
Furthermore, the endpoint may be a combination of continuous and discrete outcomes which are
collapsed in to a single binary responder index.
Table 1 shows examples of diseases that use composite endpoints combining multiple continuous
and discrete components. Responders in fibromyalgia must respond in two continuous and one or-
dinal component however responders in trials for frailty or soft tissue infections must respond in a
total of five continuous and discrete components. Generally, these composite responder endpoints
will be treated as a single binary outcome and analysed using a logistic regression model, which
we term the standard binary method. This solves problems with multiplicity however results in
large losses in efficiency (Wason and Seaman (2013)). The aim of this paper is to propose a joint
modelling framework within which we can model the components of the composite, retaining
the information on the original scales of the outcomes, hence increasing efficiency. One likelihood
based method for handling mixed data is the factorisation model. The objective is to factorise the
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Table 1. Examples of diseases that use complex composite endpoints combining multiple discrete and
continuous measures to determine effectiveness of a treatment including criteria for response and how
each component is measured
Disease Responder endpoint Measured by
Fibromyalgia • achieved a 30% improvement in Electronic diary
pain
• 30% improvement in functional Subscale of Fibromyalgia Impact
status Questionnaire (FIQ)
• improved, much improved, or 7-point Patient Global Impression of
very much improved Change (PGIC) scale
Frailty • BMI<18.5 kg/m2 OR >10% weight and height
weight loss since last wave
• One positive answer to exhaustion CES-D questionnaire
questions
• Low grip strength (M < 31.12 kg, Eg. Jamar hand dynamometer
F < 17.60 kg)
• Gait speed (M < 0.691 m/s, Distance/time
F < 0.619 m/s)
• Low activity (M < 16.5 activity Activity units derived using intensity
units, F < 13.5 activity units) vs. frequency
Necrotizing • Alive until day 28 yes/no
Soft Tissue • Day 14 debridements 6 3 surface area
Infections • No amputation if debridement yes/no
• Day 14 mSOFA score 6 1 mSOFA score - composite additively
combining scores in different systems
• Reduction of at least 3 score mSOFA score - composite additively
points in mSOFA score combining scores in different systems
Systemic lupus • Change in SLEDAI 6 -4 SLE Disease Activity Index
erythematosus • Change in PGA < 0.3 Physicians Global Assessment
• No Grade A or more than one British Isles Lupus Assessment Group
Grade B in BILAG
• Reduction in oral corticosteroids Notes
joint distribution and fit a univariate model to each component of the factorisation (de Leon and
Carriere (2013)). This accounts for correlations between the outcomes by including one response
as a covariate in the model for the other response. In the graphical modelling literature this has
been termed the ‘Conditional Gaussian Distribution’ (Whittaker (1990); Lauritzen and Wermuth
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(1989)). An advantage of these methods in relation to the composite endpoint problem is that
we may account for correlations between measurements whilst making inference directly on the
outcomes that we have measured, hence they fall within a broader class of ‘direct methods’. Ex-
amples of applications of these ideas, which build on the work of Olkin and Tate (1961), include
developmental toxicity studies by Fitzmaurice and Laird (1995) and in the longitudinal setting,
the augmented binary method was developed for application to composite endpoints in clinical
trials where the composite is formed of one continuous and one binary outcome (Wason and
Seaman (2013); Wason and Jenkins (2016); McMenamin and others (2018)). One difficulty with
these methods beyond the bivariate scenario is the range of possibilities for the factorisations,
with no consensus on how this should be determined. In the case of the SLE responder endpoint
with four components, this amounts to 24 possible factorisations, each of which may result in
different conclusions (Verbeke and others (2014); de Leon and Carriere (2013)).
Another family of models used to model mixed outcome types which feature frequently in eco-
nomics and finance are copulas. These are functions that join or couple multivariate distribution
functions to their uniform one-dimensional marginal distribution functions as discussed by Nelsen
(1999). Copulas offer a flexible framework in this setting, as the marginal distribution functions
need not come from the same parametric family. While the construction of copulas is considered
to be mathematically elegant and the flexibility with which we can model appealing, they are not
without their shortcomings. Extensions beyond the bivariate setting are difficult and have failed
to perform well in many applications (de Leon and Carriere (2013)). Other practical implications
include poor out-of-sample predictions due to the wide variety of copulas available. These restric-
tions, along with difficulties in longitudinal settings with unbalanced data structures, have seen
few applications of copulas for mixed outcome types in the medical statistics literature (Verbeke
and others (2014)). Applications of copulas in mixed outcome settings include de Leon and Wu
(2010) and Wu and de Leon. A.R. (2014).
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Another likelihood based method that allows for more flexibility when modelling the correlations
between outcomes falls within the framework of latent variable models (Skrondal and Rabe-
Hesketh (2004)). The multiple outcomes are assumed to be physical manifestations of some
underlying latent process. This is modelled by including the same latent variable in each of the
models for the observed responses. The outcomes are then assumed to be independent condi-
tional on this latent variable. This solves the problem of deciding the order of factorisations in
previously discussed methods however this formulation results in the inclusion of some covariance
parameters in the mean structure, leaving the model sensitive to misspecification of the correla-
tion structure (Sammel and Ryan (2002)). One example of these models is introduced by Sammel
and others (1997), where effects of covariates of interest are modelled through this shared latent
variable. Although these models have the intuitive interpretation that each outcome is attempting
to capture underlying disease activity, the correlation matrix is restricted to allow for the same
correlation between each pair of outcomes, which is unlikely in practice. This structure is relaxed
in work by Dunson (2000), where the effects of covariates are included in the model separately
from the latent variable. The correlation structure can be further relaxed to allow for a different
latent variable for each outcome, meaning that pairs of outcomes are not assumed to have the
same correlation. However these models would require integrating out each of the latent variables
in order to obtain the joint distribution of interest (McCulloch (2008)). Furthermore, they are
relevant in applications with multiple time points however less so for a single time point, as is
the case for the composite endpoint problem.
Latent variables have also been used in the setting of mixed continuous and discrete variables to
a different end. Namely, the outcomes adopt a correlated Gaussian distribution by assuming that
the discrete outcomes are coarsely measured manifestations of underlying continuous variables
subject to some threshold specifications, as seen in Ashford and Sowden (1970) and Chib and
Greenberg (1998). Specifying discrete variables in terms of a partitioning of the latent variable
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space into non-overlapping intervals dates back to Pearson (1904) in relation to his generalised
theory of alternative inheritance and has received much consideration in the literature since. Ter-
minology surrounding these models is inconsistent but they are often referred to as multivariate
probit models (Ashford and Sowden (1970)). This theory can also be found to underpin condi-
tional grouped continuous models (Poon and Lee (1987)). By formulating the distribution in this
way, we can correlate the error terms between models and work within the familiar paradigm
of Gaussian distributions and maximum likelihood theory. The theory and application of these
ideas for a mixture of continuous and binary outcomes has featured in the statistics literature,
see for example work by Tate (1955), Cox and Wermuth (1992) and Catalano and Ryan (1992).
Generalisations of these ideas, which appear less frequently in the literature, lead to methods
for modelling continuous and ordinal variables, with applications in developmental toxicology
(Catalano (1997); Samani and Ganjali (2008); Arminger and Kusters (1988); Regan and Cata-
lano (2000); Faes and others (2002)). Despite the advantages, the multivariate probit model has
not realised its full potential in the applied biostatistics literature. This was noted by Lessafre
and Molenberghs (1991) and we believe it still to be the case today. The few applications that do
appear tend to demonstrate bivariate scenarios or those that mix continuous and binary or con-
tinuous and ordinal, rather than all three. Furthermore, these models have not been considered
specifically to address challenges with modelling composite endpoints. Other work has combined
thresholding the response variables and introducing latent variables in the model, examples in-
clude work by Gueorguieva and Agresti (2001), de Leon and Carriere (2013), Gueorguieva and
Sanacora (2003) and Gueorguieva and Sanacora (2006), however these ideas are most applicable
in the longitudinal setting. We will therefore employ the latent outcome framework and investi-
gate its use for the composite endpoint problem.
The paper proceeds as follows. In Section 2 we discuss systemic lupus erythematosus (SLE), the
motivating example for the methods. In Section 3 we introduce the latent variable model and
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discuss how we conduct estimation and inference. In Section 4 we compare the behaviour of the
latent variable model with the augmented binary and standard binary methods, including the
case when the key assumptions are not satisfied. In Section 5 we apply the methods to the Phase
IIb MUSE trial in patients with moderate to severe SLE. Finally, in Section 6 we discuss our
findings and make some recommendations.
2. Motivating example
In what follows we will focus specifically on systemic lupus erythematosus (SLE), however the
methods introduced will be relevant to other diseases using endpoints with a similar structure. The
SLE endpoint is shown in Figure 1. It combines a continuous PGA measure, a continuous SLEDAI
measure, an ordinal BILAG measure and a binary corticosteroids measure, where patients must
meet the response criteria in all components in order to be classed as a responder overall. Note that
the SLEDAI and BILAG measures are themselves composite scores deriving from a combination
of items, however this will not be considered in the analysis.
The real data underpinning this motivation comes from the MUSE study (Furie and others
(2017)). It was a Phase IIb, randomised, double-blind, placebo-controlled study investigating the
efficacy and safety of anifrolumab in adults with moderate to severe SLE. Patients (n=305) were
randomised to receive anifrolumab (300mg or 1000mg) or placebo, in addition to standard therapy
every 4 weeks for 48 weeks. The primary end point was the percentage of patients achieving an
SRI response at week 24 with sustained reduction of oral corticosteroids (<10mg/day and less
than or equal to the dose at week 1 from week 12 through 24). The methods discussed will make
inference at one time point, as this is the case in the trial, although they can be easily extended
for the longitudinal case.
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Fig. 1. Structure of the composite endpoint use in trials of systemic lupus erythematosus. The continuous
SLEDAI, continuous PGA and ordinal BILAG measures are dichotomised and combined to form the
binary SRI indicator which is then combined with the binary taper variable to form the overall binary
SLE responder index
3. Methods
3.1 Notation
Let Yi = (Yi1, Yi2, Y
∗
i3, Y
∗
i4) represent the vector of observed and latent continuous measures for
patient i. Yi1 and Yi2 are the observed continuous SLEDAI and PGA measures. Let Yi3 denote
BILAG, the observed ordinal manifestation of Y ∗i3 and Yi4 the observed binary taper variable for
Y ∗i4. Ti represents the treatment indicator for patient i, yi10 and yi20 are the baseline measures
for Yi1 and Yi2 respectively.
3.2 Model
The mean structure for the outcomes is shown in (3.1). The baseline measures y10 and y20 are
included in the model for Y1 and Y2 respectively.
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Yi1 = α0 + α1Ti + α2yi10 + εi1
Yi2 = β0 + β1Ti + β2yi20 + εi2
Y ∗i3 = γ1Ti + ε
∗
i3
Y ∗i4 = ψ0 + ψ1Ti + ε
∗
i4
(3.1)
The observed discrete variables are related to the latent continuous variables by partitioning
the latent variable space, as shown in (3.2). The lower and upper thresholds for both discrete
variables are set at τ03 = τ04 = −∞, τ53 = τ24 = ∞. The intercept term for the ordinal variable
in (3.1) is set at γ0 = 0 so that the cut-points τ13, τ23, τ33, τ43 may be estimated. The intercept
for the binary outcome ψ0 may be estimated, as τ14 = 0.
Yi3 =

Grade E if τ03 6 Y ∗i3 < τ13,
Grade D if τ13 6 Y ∗i3 < τ23,
Grade C if τ23 6 Y ∗i3 < τ33,
Grade B if τ33 6 Y ∗i3 < τ43,
Non-responder if τ43 6 Y ∗i3 < τ53
Yi4 =
{
0, if τ04 6 Y ∗i4 < τ14,
1, if τ14 6 Y ∗i4 < τ24
(3.2)
Following these assumptions, we can model the error terms in (3.1) as multivariate normal
with zero mean and variance-covariance matrix Σ, as shown in (3.3). Note that the error variances
for ε∗3, ε
∗
4 are σ3 = 1 and σ4 = 1. This does not represent a constraint on the model but rather a
rescaling required for identifiability.
(εi1, εi2, ε
∗
i3, ε
∗
i4) ∼ N(0,Σ) Σ =

σ21 ρ12σ1σ2 ρ13σ1 ρ14σ1
ρ12σ1σ2 σ
2
2 ρ23σ2 ρ24σ2
ρ13σ1 ρ23σ2 1 ρ34
ρ14σ1 ρ24σ2 ρ34 1
 (3.3)
Subsequently, we may factorise the joint likelihood contribution for patient i as shown below.
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l(θ; Y) = f(Yi1, Yi2;θ)f(Y
∗
i3, Y
∗
i4|Yi1, Yi2;θ) (3.4)
where θ is a vector which contains all model parameters. The observed likelihood can then
be expressed as in (3.5).
l(θ; Y) =
n∏
i=1
5∏
w=1
2∏
k=1
f(Yi1, Yi2;θ) [pr (Yi3 = w, Yi4 = k|Yi1 = yi1, Yi2 = yi2;θ)]I{Yi3=w,Yi4=k}
(3.5)
The joint probability of patients having discrete measurements Yi3 = w and Yi4 = k must be
multiplied over the five ordinal levels and two binary levels resulting in ten combinations of the
probabilities in (3.6) to be calculated. We discuss the intuition for (3.6) in Appendix A.
pr (Yi3 = w, Yi4 = k|Yi1 = Yi1, Yi2 = Yi2;θ) =
Φ2
(
τw3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2
)− Φ2 (τ(w−1)3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2)−
Φ2
(
τw3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
+ Φ2
(
τ(w−1)3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
(3.6)
where Φ2 is the bivariate standard normal distribution function and µ3|1,2, µ4|1,2 and Σ3,4|1,2
are derived using the rules of conditional multivariate normality, resulting in (3.7).
µ3|1,2 =µ3 +
(ρ13−ρ12ρ23)
σ1(1−ρ212)
(Yi1 − µ1) + (ρ23−ρ12ρ13)σ2(1−ρ212) (Yi2 − µ2)
µ4|1,2 =µ4 +
(ρ14−ρ12ρ24)
σ1(1−ρ212)
(Yi1 − µ1) + (ρ24−ρ12ρ14)σ2(1−ρ212) (Yi2 − µ2)
(3.7)
Σ3,4|1,2 =
 1− ρ213−2ρ12ρ13ρ23+ρ2231−ρ212 ρ34 − ρ13ρ14−ρ12ρ13ρ24−ρ12ρ14ρ23+ρ23ρ241−ρ212
ρ34 − ρ13ρ14−ρ12ρ13ρ24−ρ12ρ14ρ23+ρ23ρ241−ρ212 1−
ρ214−2ρ12ρ14ρ24+ρ224
1−ρ212

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3.3 Estimation
As the variance parameters (σ1, σ2) are required to be greater than 0, we introduce parameters
(δ1, δ2) such that σ1 = exp(δ1) and σ2 = exp(δ2). This transformation ensures that the variance
is above 0 whilst allowing the parameter we estimate to take any real value. We must also
ensure that the correlation parameters (ρ12, ρ13, ρ14, ρ23, ρ24, ρ34) are estimated within (-1,1) by
introducing (δ12, δ13, δ14, δ23, δ24, δ34), where ρ12 = 2expit(δ12) − 1, ρ13 = 2expit(δ13) − 1, ρ14 =
2expit(δ14)− 1, ρ23 = 2expit(δ23)− 1, ρ24 = 2expit(δ24)− 1, ρ34 = 2expit(δ34)− 1.
We fit the model in R by coding the likelihood function, probability of response and using the
delta method to obtain standard errors. The bivariate distribution functions in (3.6) are estimated
using ‘pmvnorm’, using the method of Genz (1992). The likelihood maximisation is conducted
using the ‘nlminb’ function in the ‘optimx’ package, which is the best performing method in terms
of accuracy and convergence rate, however is the slowest. We use the ‘Hessian’ function in the
‘numDeriv’ package to obtain the Hessian matrix and invert this to get the covariance matrix
of the model parameters. In a small number of cases the Hessian is not positive definite because
of computational error, meaning that it cannot be inverted. This is rectified in these cases by
using the ‘near PD’ function in the ‘Matrix’ package, which computes the nearest positive definite
matrix.
3.4 Inference
We wish to make inference on the probability of response. Let Si be an indicator for patient
i denoting whether or not they achieved response defined by Si=1 if Yi1 6 θ1, Yi2 6 θ2, Y ∗i3 6
θ3, Y
∗
i4 6 θ4. Therefore,
P (Si = 1 | Ti, yi10, yi20) =
∫ θ1
−∞
∫ θ2
−∞
∫ θ3
−∞
∫ θ4
−∞
fY(Y;Ti, yi10, yi20)dy
∗
i4dy
∗
i3dyi2dyi1 (3.8)
We obtain the integrand in (3.8) by using the fitted values of the parameters in the conditional
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mean and conditional covariance matrix in (3.7). Parameter estimates from these methods are
maximum likelihood estimates and so we avail of asymptotic maximum likelihood theory. The
integral in (3.8) is evaluated using the ‘R2Cuba’ package to obtain estimates for each patient,
assuming they were treated p˜i1 and not treated p˜i0. The odds ratio treatment effect is then defined
as shown in (3.9).
δ˜ =
( ∑N
i=1 p˜i1
N −∑Ni=1 p˜i1
)
( ∑N
i=1 p˜i0
N −∑Ni=1 p˜i0
) (3.9)
Note that we can easily define a risk difference or risk ratio using these quantities but in what
follows we consider δ˜ to be the effect of interest. The standard error estimates are obtained using
the delta method. This requires the covariance matrix of the maximum likelihood estimates
Cov(θˆ) and ′′δ˜, the vector of partial derivatives of δ˜ with respect to each of the parameter
estimates. The variance of δ˜ is obtained as shown in (3.10).
V ar(δ˜) = (′′δ˜)TCov(θˆ)(′′δ˜) (3.10)
Alternatively, the quantity in (3.8) can also be considered to be a multivariate Gaussian
hidden truncation distribution, from which we can obtain a closed form solution, and proceed as
detailed by Arnold (2009).
Another important consideration for the model is how to assess goodness-of-fit. We propose an
extension to an existing method for application in this case, which is detailed in Appendix B in
the supplementary material.
4. Simulation study
We are interested in comparing the performance of the latent variable, augmented binary and
standard binary methods through simulation. The models for the augmented binary and standard
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binary methods are included in Appendix C in the supplementary material.
4.1 Data generating model
Initially, we investigate the properties of the methods when the assumptions of the latent variable
model are satisfied. The parameter values in the ‘baseline’ scenario are chosen to simulate a
scenario where composite endpoints are typically recommended for use. Namely, that all four
components drive response and items are correlated but not so highly that the composite becomes
redundant. The parameter values have been informed by the MUSE trial dataset, in particular the
correlation structure. The response probability in the control arm is 0.275 and in the treatment
arm is 0.381, resulting in an odds ratio equal to 1.6, values typically observed in trials requiring
response in all four components. The parameter values selected for the model in (3.1) are shown in
Table 2. From this baseline case, we vary parameters to determine how the methods behave under
various scenarios of interest. In particular, under varying treatment effect, varying responder
threshold and varying drivers of response. The parameter values for these data generating models
are included in Appendix D in the supplementary material.
Table 2. Parameter values for the data generating model in the baseline simulation scenario comparing
the performance of the latent variable, augmented binary and standard binary methods for analysing
a composite endpoint, where the values correspond to a treatment effect in all components and all
components drive response
Purpose Values
Total sample size N=300
Intercept α0 = −4.9, β0 = −1.2, ψ0 = −0.2
Treatment α1 = −0.28, β1 = −0.35, γ1 = −0.24, ψ1 = −0.18
Baseline value α2 = −0.5, β2 = −0.5
Variance σ1 = σ2 = 1
Correlation ρ12 = 0.5, ρ13 = ρ24 = 0.35, ρ14 = 0.25, ρ23 = 0.4, ρ34 = 0.3
Discrete cut-point τ13 = −1, τ23 = −0.1, τ33 = 0.45, τ43 = 1.3
Responder threshold θ1 = −4, θ2 = −0.6, θ3 = 0.45, θ4 = 0
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4.2 Results
The methods are evaluated against a range of performance criteria, which are included with their
Monte Carlo standard errors in Appendix E of the supplementary material. For further details
see Morris and others (2017).
4.2.1 Varying treatment effect Figure 2 shows the bias of the methods as the treatment effect
varies. The standard binary method is unbiased, as we would expect for a logistic regression
in a large sample. The latent variable method is unbiased for smaller treatment effects but a
small bias towards the null is introduced as the treatment effect increases. The augmented binary
method is biased away from the null in this setting and the bias increases as the treatment effect
increases. Given that this performance is worse than is suggested from previous applications of
the augmented binary method in Wason and Seaman (2013) and Wason and Jenkins (2016), this
would suggest that the treatment effect from the augmented binary method may be biased if the
model is misspecified. The coverage of the methods is shown in Figure 3. The binary method has
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Fig. 2. Bias reported from the latent variable method, augmented binary method and standard binary
method when nsim=5000, total sample size N=300 for true log-odds treatment effect between 1.2 and 2.2.
The composite endpoint of interest contains four components: two continuous, one ordinal, one binary
and treatment effects are present in all four components
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approximately nominal coverage. The latent variable method has nominal coverage for smaller
treatment effects, however the coverage probability decreases as the treatment effect increases.
The augmented binary method has coverage of approximately 0.91, which also decreases when the
treatment effect increases. In order to diagnose this under-coverage in the joint modelling methods
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Fig. 3. Coverage probability reported from the latent variable method, augmented binary method and
standard binary method for nsim=5000, total sample size N=300 for true log-odds treatment effect
between 1.2 and 2.2. The composite endpoint of interest contains four components: two continuous, one
ordinal, one binary and treatment effects are present in all four components
we can look at bias-corrected coverage, as recommended in Morris and others (2017). Figure 4
shows both the coverage and bias-corrected coverage for the three methods. The properties of the
standard binary method remain unchanged. The bias-corrected coverage of the latent variable
method is 0.95, which indicates that any under-coverage is due to the bias present. This is not true
for the augmented binary method which shows small improvements in bias-corrected coverage,
indicating that under-coverage is present in this method due to reasons other than bias. Again,
this may be down to model misspecification. The power of the three methods is shown in Figure
5. The performance of the binary and augmented binary methods are as we would expect based
on previous findings in Wason and Seaman (2013) and Wason and Jenkins (2016). The latent
variable method offers much higher power. In this setting it has close to 100% power for odds
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Fig. 4. Coverage probability (left) and bias-corrected coverage probability (right) reported from the latent
variable method, augmented binary method and standard binary method for nsim=5000, total sample
size N=300 for true log-odds treatment effect between 1.2 and 2.2. The composite endpoint of interest
contains four components: two continuous, one ordinal, one binary and treatment effects are present in
all four components
ratios larger than 1.6, an effect that is plausible to observe in a trial. These findings have indicated
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Fig. 5. Statistical power reported from the latent variable method, augmented binary method and stan-
dard binary method for nsim=5000, total sample size N=300 for true log-odds treatment effect between
1.2 and 2.2. The composite endpoint of interest contains four components: two continuous, one ordinal,
one binary and treatment effects are present in all four components
that the standard binary method has the smallest bias and that the latent variable method has
the smallest variance. The mean squared error (MSE) provides a combined measure of bias and
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variance. Figure 6 shows the MSE of the three methods as the treatment effect varies. The MSE
for the standard and augmented binary methods is approximately 6.5 times that of the latent
variable method. However, this measure should be interpreted with care due to the fact that the
MSE is more sensitive to the sample size than comparisons of bias or empirical SE alone (Morris
and others (2017)).
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Fig. 6. Mean Squared Error (MSE) reported from the latent variable method, augmented binary method
and standard binary method for nsim=5000, total sample size N=300 for true log-odds treatment effect
between 1.2 and 2.2. The composite endpoint of interest contains four components: two continuous, one
ordinal, one binary and treatment effects are present in all four components
4.2.2 Varying θ1 To understand more about the precision performance of the augmented binary
method in particular, we vary the responder threshold θ1 to change the proportion of responders
in that outcome. Figure 7 shows the density of the Y1 variable and the relative precision of
the methods, as the responder threshold varies. The precision gains from the augmented binary
method diminish as the threshold increases. This is intuitive, as improvements in efficiency fall as
the continuous component becomes less responsible for driving response. It is interesting to note
that all precision gains are lost for any thresholds above -4. Therefore, even when 20% of patients
are non-responders, all efficiency gains are lost. The percentage of responders needed to improve
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efficiency using the augmented binary method will of course depend on the correlation structure
employed. Due to the additional information in the other components, the latent variable method
is still five times as precise as the other methods.
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Fig. 7. Density of continuous Y1 variable (left) and estimated relative precision of augmented binary versus
standard binary method, latent variable versus augmented binary method and latent variable versus
standard binary method as the Y1 responder threshold θ1 varies between θ1 = −6 and θ1 = −2 (right) for
nsim=5000 and total sample size N=300. The composite endpoint of interest contains four components:
two continuous, one ordinal, one binary and treatment effects are present in all four components
4.2.3 Components contributing to response An important consideration when investigating per-
formance is how the precision changes when different combinations of outcomes are responsible for
driving response. Figure 8 shows boxplots of the relative precision for the methods for four differ-
ent response combinations, namely when response is driven by (Y1, Y2, Y3, Y4), (Y1, Y2, Y3), (Y1, Y4)
and (Y4), where Y1 and Y2 are observed as continuous variables, Y3 is ordinal and Y4 is binary.
When all four components contribute to response, the latent variable method outperforms the
other methods, offering large precision gains. The variability in the magnitude of these gains is
large, with the median result showing that the latent variable method reports the treatment effect
8 times more precisely than the binary method and 6 times more precisely than the augmented
binary method. If response is driven by (Y1, Y2, Y3) then the relative median gains for the latent
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Fig. 8. Estimated relative precision gains from augmented binary versus standard binary method, latent
variable versus augmented binary method and latent variable versus standard binary method when differ-
ent combinations of components driving response. Response driven by Y1, Y2, Y3, Y4 (top left), Y1, Y2, Y3
(top right), Y1, Y4 (bottom left) and Y4 (bottom right) where Y1, Y2 are continuous, Y3 is ordinal, Y4 is
binary for nsim=5000 and total sample size N=300. The composite endpoint of interest contains four
components: two continuous, one ordinal, one binary and treatment effects are present in all four com-
ponents
variable method are larger, however note that in less that 2% of cases the treatment effect is
reported equally or less precisely than from both of the other methods. The findings are similar
when response is driven by (Y1, Y4), however the median gains are much smaller. The treatment
effect is reported 5 times more precisely from the latent variable method than the binary method
in this setting. Note that as the augmented binary method models the relevant components it still
performs well and again better than the latent variable method in a very small number of cases.
When binary Y4 determines response, the augmented binary method offers no improvement in
precision whereas the latent variable method is approximately 1.5 times more precise. It is clear
from the results that the magnitude of the precision gains from the latent variable method is
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highly dependent on the structure of the data.
4.3 Sensitivity analysis
The key assumptions in this model are that of joint normality of the four components and that
the discrete variables are realisations of latent continuous variables. Although it is not possible
to test these assumptions in real data, we can investigate how robust the latent variable method
is to deviations from these conditions. We can do this by drawing from the multivariate skew-
normal distribution with different degrees of skew in each of the components. The first scenario
investigated considers when all four components are skewed. Scenarios 2-3 consider different
magnitudes of skew in the latent continuous components only. This tests the robustness of the
method to the assumption that the observed discrete variables manifest from a true normal
continuous variable. Scenario 4 is the null case for scenario 3. The results are shown in Appendix
F of the supplementary material.
In summary, scenarios 1-3 have increased bias resulting in under-coverage as the bias-corrected
coverage is close to nominal for all scenarios. The coverage of the latent variable method is nominal
in the null case. This is consistent with our previous findings however the magnitude of the bias
is much smaller when the assumptions are satisfied. The latent variable method still offers large
power gains over the other methods. The MSE is smallest for the latent variable method across
all scenarios investigated, indicating that the large reduction in variance is useful despite the
introduction of bias. The latent variable method estimates the probability of response in the
control arm well however underestimates the probability of response in the treatment arm. The
magnitude of this underestimation is unaffected by the degree of skew or whether the skew
is present in the observed continuous components. The relative precision of the methods are
consistent with our previous findings indicating that the violation of joint normality only affects
the bias and not the variance. The augmented binary and standard binary methods behave
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similarly to when the joint normality assumptions are satisfied, which is expected given that the
assumptions of those models are violated in both contexts.
5. Case study
5.1 Data structure
Due to data sharing policy, we conduct the analysis for a subset of the patients, N=278 rather
than N=305 reported in the paper, so the results will differ from the original paper. Furthermore,
only the anifrolumab 300mg arm (n=95) and the placebo arm (n=87) will be used to illustrate
the methods.
The simulation results have suggested that the structure of the data is important for how the
methods will perform, in particular the magnitude of the precision gains depends highly on which
components drive response. Table 3 shows the criteria for response in each component and the
rates of response in each by treatment arm. This suggests that the components responsible for
responder discrimination are the continuous SLEDAI measurement and the binary taper measure.
We can further explore the structure of the data by visualising the 4-D endpoint. Figure 9 shows
a plot of the four components in the SLE index. The two panels show taper responders and
non-responders, the levels in BILAG are denoted using colours where any coloured data points
representing Grade B - Grade E are responders. The response thresholds for the continuous
measurements are included, where a patient must be below the threshold to be considered a
responder. We can conclude that response is entirely driven by SLEDAI and the taper variable,
as there are no PGA non-responders not already accounted for by SLEDAI and no purple data
points in the responder quadrant.
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Table 3. Observed response rates in each of the SLE responder index components in the anifrolmab 300mg
arm and placebo arm of the Phase IIb MUSE trial. SLE index is comprised of a continuous SLEDAI
outcome, continuous PGA outcome, ordinal BILAG outcome and binary taper outcome where response
in each component is achieved when the patient meets the criteria shown
Components Response criteria Treatment arm
Anifrolumab 300mg Placebo
SLEDAI Change in SLEDAI 6 -4 58/89 41/76
PGA Change in PGA < 0.3 87/89 75/76
BILAG No Grade A or more than 86/89 72/76
one Grade B
Taper Sustained reduction in 53/95 37/87
oral corticosteroids
SLE responder index Responder in all four components 34/95 18/87
Taper responder Taper non−responder
−20
−10
0
−2 −1 0 −2 −1 0
PGA
SL
ED
AI
BILAG
Grade E
Grade D
Grade C
Grade B
Non−responder
Fig. 9. Observed response rates in each of the SLE responder index components in the Phase IIb MUSE
trial. SLEDAI is plotted on the y-axis and PGA on the x-axis, along with their corresponding dichotomi-
sation thresholds. Levels of BILAG are represented by different colours and taper responders and non-
responders are split across two panels.
5.2 Results
The probability of response in the placebo arm is estimated as 0.199 by the latent variable
method, 0.211 by the augmented binary method and 0.224 by the standard binary method.
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A much larger discrepancy between the methods is shown in the treatment arm, where the
probability of response is estimated at 0.311, 0.324 and 0.382 in the latent variable, augmented
binary and standard binary methods respectively.
The log-odds treatment effect point estimates and confidence intervals for the MUSE trial are
shown in Table 4. Both joint modelling methods estimate the treatment effect more precisely.
Although there may be bias present in the point estimates for the joint modelling methods, the
confidence intervals entirely overlap with that of the binary method. All three methods indicate
that anifrolumab 300mg performs better than placebo, as in the original findings. The latent
variable model fits the data well according to the modified Pearson residuals, see Appendix G.
The simulation results indicated that the latent variable method may report the treatment
effect with bias and have problems with bias related under-coverage when the treatment effect
is large and when the assumption of joint normality is not satisfied. As the problems with the
performance are bias related, we suggest implementing a bootstrap procedure to correct for this.
In this scenario N=182 and nboot=1000, therefore the procedure is as follows:
1. Sample with replacement N=182 patients from the MUSE trial
2. Compute the treatment effect using the latent variable, augmented binary and standard
binary methods
3. Repeat step 1 and 2 nboot=1000 times
4. Obtain an estimate of the bias using the difference between the treatment effect in the
MUSE trial and the mean of the bootstrap treatment effects
A 95% bootstrap confidence interval for the treatment effect estimate can be obtained by
ordering the 1000 bootstrap estimates of the treatment effect and taking the 25th and 975th
estimate. The point estimates and 95% confidence intervals from the MUSE trial and from the
bootstrap re-sampling are shown in Table 4. The log-odds point estimate from the latent variable
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Table 4. Log-odds treatment effect estimates and 95% confidence intervals from the latent variable
method, augmented binary method and standard binary method in the Phase IIb MUSE trial and the
bootstrap sample when N=182 and nboot = 1000
Method Log-odds treatment effect
MUSE trial estimate Bootstrap estimate
Latent Variable 0.641 (0.217, 1.072) 0.682 (0.275, 1.137)
Augmented binary 0.580 (0.139, 1.021) 0.608 (0.096, 1.111)
Binary 0.763 (0.078, 1.449) 0.809 (0.112, 1.561)
method has been shifted away from the null by approximately 0.04. This is the magnitude of
bias that the simulation results suggested for this treatment effect. The width of the confidence
interval hasn’t changed much from the original estimate in the bootstrap sample, indicating that
the variance is well estimated in the trial dataset. The point estimate for the binary method has
also been shifted substantially, despite the simulations showing this method to be unbiased. This
is likely due to the large imprecision in the treatment effect reported by the binary method.
In terms of estimated precision, it is interesting to determine where the trial data set lies in
the distribution of datasets generated in the simulation study. The latent variable method reports
the treatment effect 2.5 times more precisely than the standard binary method in this setting,
whilst the augmented binary method is 2.4 times more precise. We would have expected this
similar performance as the augmented binary method models the SLEDAI and taper variables -
the only components driving response. This increase in precision from the latent variable method
compared with the binary method amounts to a 60% reduction in required sample size.
6. Discussion
In this paper we addressed the issue of substantial losses of information when modelling complex
composite endpoints. By employing concepts of partitioning latent variable outcome spaces we
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could model the observed structure of the composite endpoint, which resulted in large gains
in efficiency. Sensitivity analyses showed that a bias is introduced when the assumptions of
joint normality were not satisfied, however similar reductions in variance were observed. When
applying the methods to the MUSE trial, we implemented a bootstrap procedure to correct for
the presumed bias, as joint normality could not be assessed. The treatment effect was reported
2.5 times more precisely than that reported from the standard binary method.
Bias correction appears to perform well in the real data, where the crucial assumptions cannot
be tested. The point estimate is shifted by a magnitude that would have been expected from
the simulation results and the estimate of the variance is similar to that obtained in the single
trial dataset. Furthermore the bootstrap confidence interval for the treatment effect is contained
within that for the binary method, which offers further reassurance for application. However,
more work could be done to investigate different structures and scenarios to ensure that the bias
correction is always performing as expected. Ideally, we would investigate this further across a
large number of datasets however this is too computationally intensive. To perform this on one
replicate, where nboot = 1000 using 200 cores on a high performance computer (HPC) currently
takes 7 hours. Exploring this further through bootstrapping or employing alternative multivariate
distributions is an area for future research.
The precision gains offered by the latent variable method offer justification for the additional
complexity. However, the magnitude of these gains are highly dependent on the components that
drive response. The baseline case in the simulations was chosen to reflect when a composite
endpoint is recommended for use, i.e. when all four components determine response rates. In this
scenario, the precision gains achieved resulted in the latent variable method reporting the effect
2.5 to 17.5 times more precisely than the standard binary method. However, in practice in SLE
trials, this has not been found to be the case. A review of two phase 3 trials (N= 2262) using the
SRI-5 index found the SRI-5 response rate at week 52 for all patients was 32.8% (Kalunian and
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others (2018)). Non-response due to a lack of SLEDAI improvement, concomitant medication non-
compliance or dropout was 31, 16.5 and 19.1%, respectively. Non-response due to deterioration
in BILAG or Physicians Global Assessment after SLEDAI improvement, concomitant medication
compliance and trial completion was 0.5%. This is in agreement with our findings from the
MUSE trial data, which suggests that the precision gains in the baseline case are optimistic. The
simulation results show that when one continuous and one binary component drive response, the
latent variable method may be anywhere between 1 and 12 times as precise as the binary method
and up to 7 times as precise as the augmented binary method. In a very small number of cases
(<2%) there are no efficiency gains from using the latent variable method in this scenario. However
the potential gains available in 98% of cases ensures that implementing the latent variable method
is still very much a worthwhile endeavour, for all stakeholders in a clinical trial.
In addition to SLE, we have identified other disease areas that have a similar complex composite
structure, meaning the potential to improve efficiency extends well beyond SLE. However, it
must be acknowledged that the exact structure of the endpoint may offer different magnitudes
of bias and precision, and may require longer computational time. Furthermore, in conditions
where longitudinal data is required to sufficiently capture disease activity, trials may include
multiple follow-up times and the method will need to be extended to include latent variables in
the mean structure to account for this. In terms of scalability to more complex endpoints, the
computational time depends on many things, in particular the number of outcomes, the outcome
scale and the number of levels in the ordinal variable. In our case, we find the number of ordinal
levels to be the most influential factor in computational time. This is due to the fact that 5
levels in the ordinal variable leads to 10 probability calculations in (3.6), however 3 levels would
require the computation of 6 joint probabilities. Consequently, the run time will be substantially
increased if there are multiple ordinal levels and decreased if the discrete variables are binary. If
the computational time for a particular endpoint is deemed to be too large, then we may reduce
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the complexity of the endpoint by collapsing the least informative components in to a single
binary variable. It must be acknowledged that as we have coded the likelihood, with no package
available to do this, the likelihood and probability of response code will have to be tailored
specifically to each endpoint. The potential gains in efficiency justify this additional complexity.
We have shown that the latent variable method is a powerful tool in composite endpoint analysis
and should be considered as a primary analysis method in a trial using these endpoints. In order
for implementation in the general case, where the composite contains any number of continuous
and discrete outcomes and to ensure the uptake of the method in clinical trials, we will need to
develop a software package. Furthermore, if patients and investigators are to benefit from the
efficiency gains, we will need a method to calculate the required sample size in a given trial. We
are currently working on addressing these issues to aid in the application of the method.
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Supplementary material
Appendix A
The joint probability below expresses, for patient i with Y1 = yi1 and Y2 = yi2, the probability
that they will have a Y3 score w and a Y4 score k.
pr (Yi3 = w, Yi4 = k|Yi1 = Yi1, yi2 = yi2;θ) =
Φ2
(
τw3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2
)− Φ2 (τ(w−1)3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2)−
Φ2
(
τw3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
+ Φ2
(
τ(w−1)3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
(A.1)
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The intuition for the joint probability can be seen below in Figure 10, specifically for the SLE
endpoint, where w = 5 and k = 2.
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Y 4
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Fig. 10. The figure shows the conditional outcome Y3|1,2 on the x-axis and Y4|1,2 on the y-axis with their
corresponding underlying continuous densities and partitioning thresholds. The area where w = 3 and
k = 2 is highlighted for illustration
The blue box indicates the region where w = 3 and k = 2. As τ03 = τ04 = −∞ and τ53 =
τ24 =∞, the corresponding probability is shown in (A.2).
pr (Yi3 = 3, Yi4 = 2|Yi1 = yi1, Yi2 = yi2;θ) =
Φ2
(
τ33 − µ3|1,2,∞− µ4|1,2; Σ3,4|1,2
)− Φ2 (τ23 − µ3|1,2,∞− µ4|1,2; Σ3,4|1,2)−
Φ2
(
τ33 − µ3|1,2, τ(14 − µ4|1,2; Σ3,4|1,2
)
+ Φ2
(
τ23 − µ3|1,2, τ14 − µ4|1,2; Σ3,4|1,2
)
(A.2)
Latent variable modelling for composite endpoint analysis 33
Appendix B
One suggestion in the literature for assessing goodness-of-fit in latent variable models is introduced
by Samani and Ganjali (2008) for the case when there is one continuous and one ordinal variable.
This may be extended to allow for two continuous, one ordinal and one binary outcome for
application in SLE, as shown below.
As before, let Yi = (Yi1, Yi2, Yi3, Yi4)
′ be the vector of observed responses for patient i. Then,
partitioning the observed and latent continuous measures, we let Ycts = (Y1, Y2) and Ydis =
(Y3, Y4). Then, Σˆ11 = ˆV ar(Ycts), Σˆ22 = ˆV ar(Ydis), Σˆ12 = Σˆ21 = ˆCov(Ycts,Ydis).
The modified Pearson residuals, taking in to account the correlation between responses are shown
below.
rpi = Σˆ
− 12 (Yi − µˆi) (B.1)
where,
µˆi = (Eˆ(Yi1, Yi2 | Xi1, Xi2), Eˆ(Yi3, Yi4 | Xi3, Xi4))′ (B.2)
and
Σˆ =
(
Σˆ11 Σˆ12
Σˆ21 Σˆ22
)
(B.3)
A Cholesky decomposition may be used to obtain Σˆ−
1
2 in (B.1). The covariance between the
vector of observed continuous and observed discrete responses is shown below.
Σ12 =E(YctsYdis)− E(Ycts)E(Ydis)
=E(YctsE(Ydis | Ycts))− E(Ycts)E(Ydis)
=E(Y1Y2E(Y3, Y4 | Y1, Y2))− E(Ycts)E(Ydis)
=
∫
y1
∫
y2
y1y2
∑
y3
∑
y4
y3y4P (Y3 = w, Y4 = k|Y1 = y1, Y2 = y2) fY1,Y2(y1, y2)dy1dy2
− E(Ycts)E(Ydis)
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Where,
P (Y3 = w, Y4 = k|Y1 = y1, Y2 = y2) =
Φ
(
τw3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2
)− Φ (τ(w−1)3 − µ3|1,2, τk4 − µ4|1,2; Σ3,4|1,2)−
Φ
(
τw3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
+ Φ
(
τ(w−1)3 − µ3|1,2, τ(k−1)4 − µ4|1,2; Σ3,4|1,2
)
E(Ycts) =
∫
y1
∫
y2
y1y2fY1,Y2(y1, y2)dy1dy2
E(Ydis) =
∑
y3
∑
y4
y3y4P (Y3 = w, Y4 = k)
and
P (Y3 = w, Y4 = k) = Φ(τw3 − µ3, τk4 − µ4; ρ3,4)− Φ(τ(w−1)3 − µ3, τk4 − µ4; ρ3,4)−
Φ(τw3 − µ3, τ(k−1)4 − µ4; ρ3,4) + Φ(τ(w−1)3 − µ3, τ(k−1)4 − µ4; ρ3,4)
The Pearson residual is based on the Pearson goodness-of-fit statistics
χ2p =
n∑
i=1
χ2p(Yi, µˆi) (B.4)
with ith component
χ2p(Yi, µˆi) = (Yi − µˆi)′Σˆ−1(Yi − µˆi) (B.5)
The distribution of the residuals should follow a chi-squared distribution with p degrees of free-
dom. Comparing the residuals to the chi-squared value allows us to identify observations which
the model does not fit well. If there are many observations unexplained by the model then it
could indicate a poor choice of model. This may be due to the covariance structure Σˆ and its
assumed distribution. The model may be refitted with various covariance structures and to obtain
a model which is found to satisfactorily explain the observed data. If this is not achieved then
joint normality of the error terms may be an unreasonable assumption indicating that the latent
variable model may not be appropriate. It is possible to fit latent variable models which assume
a different multivariate distribution for the error terms, however this is not considered here.
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Appendix C
Augmented binary method
The augmented binary model is shown below. The baseline measures for Yi1 and Yi2 are included
for comparison, as they are accounted for in the mean structure of the latent variable method.
As one time point is modelled we can use a linear model for Yi1 as shown in (C.1). Note that Yi1
or Yi2 may be chosen as the continuous measure to retain and should always be determined by
which is the most informative.
Yi1 = δ0 + δ1Ti+ δ2yi10 + δ3yi20 + εi (C.1)
where εi|Ti, yi10, yi20 ∼ N(0, σ). In this case, the failure time binary indicator will contain
information from the remaining three components. Fi is set to equal 0 if Yi2 6 θ2, Yi3 is Grade
B-E and Yi4 = 0, otherwise the patient is labelled a non-responder in these components and
Fi1 = 1. Fi is modelled using the logistic regression model in (C.2).
logit(Pr(Fi = 1|Ti, yi10, yi20) = αF + βFTi + γF yi10 + ψF yi20 (C.2)
Maximum likelihood estimates for the parameters are obtained from fitting models (C.1) and
(C.2). The probability of response is shown in (C.3).
P (Yi1 6 θ1, Fi1 = 0|Ti, yi10, yi20) =
∫ θ1
−∞
P (Fi1 = 0|Ti, yi10, yi20)fY1(yi1;Ti, yi10, yi20)dyi1 (C.3)
As in the latent variable method, (C.3) is used to obtain probability of response estimates for
each patient, assuming they were treated p˜i1 and not treated p˜i1, which are used to define an
odds ratio, risk ratio or risk difference.
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Standard binary method
The standard binary method is a logistic regression on the overall responder index, as shown in
(C.4).
logit(Pr(Si = 1|Ti, yi10) = α+ βTi + γyi10 + ψyi20 (C.4)
The odds ratio and standard error estimates can be obtained directly.
Appendix D
Table 5. Performance measures and Monte Carlo standard errors used to assess the behaviour of the
latent variable, augmented binary and binary methods in a simulation study for the systemic lupus
erythematosus composite endpoint
Performance measure Estimate MCSE
Bias 1nsim
nsim∑
j=1
θˆj − θ
√
1
nsim(nsim−1)
nsim∑
j=1
(θˆj − θ¯)2
Coverage 1nsim
nsim∑
j=1
1(θˆlow,j 6 θ 6 θˆupp,j)
√
ˆcov.(1− ˆcov.)
nsim
Bias-corrected coverage 1nsim
nsim∑
j=1
1(θˆlow,j 6 θ¯ 6 θˆupp,j)
√
ˆBEcov.(1− ˆBEcov.)
nsim
Power 1nsim
nsim∑
j=1
1(pj < α)
√
ˆPower(1− ˆPower)
nsim
MSE
nsim∑
j=1
(θˆj − θ)2
√
nsim∑
j=1
[(θˆj−θ)2− ˆMSE]2
nsim(nsim−1)
Empirical SE
√
1
nsim−1
nsim∑
j=1
(θˆi − θ¯)2 ˆEmpSE√
2(nsim−1)
Model SE
√
1
nsim−1
nsim∑
j=1
ˆV ar(θˆj)
√
ˆV ar[ ˆV ar(θˆ)]
4nsim ˆModSE
2 †
Relative precision A vs. B
ˆV ar(θˆj)B
ˆV ar(θˆj)A
-
θˆj : estimated log-odds treatment effect in simulated data j
θ¯: mean log-odds treatment effect over nsim datasets
θˆlow,j , θˆupp,j lower and upper limit of confidence interval for iteration j
† ˆV ar[ ˆV ar(θˆ)] = 1nsim−1
∑nsim
j=1 { ˆV ar(θˆi)− 1nsim
∑nsim
j=1
ˆV ar(θˆj)}2
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Appendix E
Table 6. Parameter values for the simulated scenarios which investigate the effect of varying responder
threshold θ1, changing the components driving response and differing treatment effects on the perfor-
mance of the latent variable, augmented binary and standard binary methods for the systemic lupus
erythematosus composite endpoint
Scenario Parameters Investigates
θ1 = −2 θ1 = −2 100% of patients respond in Y1
θ1 = −3 θ1 = −3 96% of patients respond in Y1
θ1 = −4 θ1 = −4 82% of patients respond in Y1
θ1 = −5 θ1 = −5 52% of patients respond in Y1
θ1 = −6 θ1 = −6 20% patients respond in Y1
Y1, Y4 θ1 = −5, θ2 = 2, θ3 = 2 Continuous and binary variabledriving response
Y4 θ1 = −2, θ2 = 2, θ3 = 2 Binary variable drivingresponse
Y1, Y2, Y3 θ4 = 2
Two continuous and ordinal
drive response
Treat case 1
α0 = −4.9, α1 = −0.09, β0 = −1.2,
β1 = −0.11, γ1 = −0.145, ψ0 = −0.2,
ψ1 = −0.07
Odds ratio = 1.217
Treat case 2
α0 = −4.9, α1 = −0.20, β0 = −1.2,
β1 = −0.25, γ1 = −0.2, ψ0 = −0.2,
ψ1 = −0.12
Odds ratio = 1.426
Treat case 3
α0 = −4.9, α1 = −0.30, β0 = −1.2,
β1 = −0.50, γ1 = −0.3, ψ0 = −0.2,
ψ1 = −0.22
Odds ratio = 1.794
Treat case 4
α0 = −4.9, α1 = −0.32, β0 = −1.2,
β1 = −0.65, γ1 = −0.39, ψ0 = −0.2,
ψ1 = −0.27
Odds ratio = 2.007
Treat case 5
α0 = −4.9, α1 = −0.33, β0 = −1.2,
β1 = −0.72, γ1 = −0.45, ψ0 = −0.2,
ψ1 = −0.33
Odds ratio = 2.198
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Appendix F
Multivariate skew-normal distribution
To test the robustness of the latent variable method to deviations from joint normality of the
components, we can generate the data so that the components are drawn from a multivariate skew-
normal. The multivariate skew-normal is an extension of the univariate skew-normal distribution
introduced by ?. They define it as follows. A random vector Y=(Y1, ...,k )
T has k-variate skew-
normal distribution, if its density function is
fk(y) = 2φk(y; Ω)Φ(α
Ty),y ∈ Rk (F.1)
where φk(y; Ω) is the probability density function of the k-variate normal distribution with stan-
dardised marginals and correlation matrix Ω. The shape parameter α determines the skewness,
where α = 0 reduces the density in (F.1) to the N(0,Ω) density.
Scenarios of interest are shown in Table 7. The first scenario considers when all four components
are skewed. Scenarios 2-3 consider different magnitudes of skew in the latent continuous compo-
nents only. This tests the robustness of the method to the assumption that the observed discrete
variables manifest from continuous variables. Scenario 4 is the null case for scenario 3.
Table 7. Simulation scenarios considered to investigate deviations from joint normality for the compo-
nents of the systemic lupus erythematosus composite endpoint based on the multivariate skew-normal
distribution where α determines the magnitude of the skew in each component
Scenario α Purpose
skew1 (0.1, 0.1, 0.1, 0.1) Skew in all four components
skew2 (0, 0, 0.1, 0.1) Skew in discrete components only
skew3 (0, 0, 0.05, 0.05) Smaller skew in discrete components only
skew4 (0, 0, 0.05, 0.05) Smaller skew in discrete components only in the null case
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Results
The bias, coverage, bias-corrected coverage and power are shown in Table 8 for all four sce-
narios. In scenarios 1-3, the non-normality introduces bias which results under-coverage. The
bias-corrected coverage is close to nominal for all scenarios however the coverage of the latent
variable method is nominal in the null case. This is consistent with our findings when the joint
normality assumption is satisfied in that bias is introduced in the estimation of the treatment
arm, however the magnitude of this bias is much smaller when the assumptions are satisfied. The
augmented binary and standard binary methods behave similarly to when the joint normality
assumptions are satisfied, which is expected given that the assumptions of those models are vi-
olated in both contexts. The latent variable method still offers large power gains over the other
methods.
Table 9 shows the MSE, empirical SE and model SE of the three methods. The latent variable
method performs best consistently across these performance measures. The augmented binary
and standard binary methods have an MSE across all scenarios of approximately 0.06 whilst
the MSE of the latent variable method is between 0.01 and 0.04. This indicates that the large
reduction in variance is useful despite the introduction of bias. We acknowledge however that this
may not hold across all sample sizes (Morris and others (2017)).
Table 10 shows the probability of response in each arm for each of the methods. The findings
are consistent with when the assumptions are satisfied. Namely, the latent variable method esti-
mates the probability of response in the control arm well however underestimates the probability
of response in the treatment arm. The magnitude of this underestimation is unaffected by the
degree of skew or whether the skew is present in the observed continuous components.
The odds ratio treatment effect estimate from each method is shown in Table 11. The latent
variable method is biased towards the null, the augmented binary method is biased away from
the null. The binary method slightly underestimates the treatment effect in this setting however
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Table 8. Operating characteristics of the latent variable, augmented binary and binary methods when the
components of the systemic lupus erythematosus endpoint are drawn from a multivariate skew-normal,
N=300 and nsim = 1000
Performance measure Scenario Method
Latent Variable Augmented Binary Binary
Bias skew1 -0.173 (0.012) 0.041 (0.252) -0.015 (0.258)
skew2 -0.103 (0.008) 0.036 (0.251) -0.020 (0.255)
skew3 -0.068 (0.008) 0.038 (0.244) -0.016 (0.245)
skew4 -0.033 (0.008) 0.007 (0.254) 0.001 (0.255)
Coverage skew1 0.556 (0.018) 0.933 (0.009) 0.939 (0.009)
skew2 0.811 (0.013) 0.928 (0.008) 0.941 (0.008)
skew3 0.884 (0.010) 0.934 (0.008) 0.950 (0.007)
skew4 0.933 (0.009) 0.923 (0.009) 0.950 (0.008)
Bias-corrected skew1 0.962 (0.007) 0.929 (0.009) 0.943 (0.008)
coverage skew2 0.936 (0.008) 0.930 (0.008) 0.943 (0.007)
skew3 0.940 (0.008) 0.929 (0.008) 0.954 (0.007)
skew4 0.948 (0.008) 0.926 (0.009) 0.950 (0.008)
Power skew1 0.897 (0.011) 0.646 (0.017) 0.487 (0.018)
skew2 0.959 (0.006) 0.637 (0.015) 0.471 (0.016)
skew3 0.982 (0.004) 0.641 (0.015) 0.495 (0.016)
skew4 - - -
all are close to true for the null case.
The median relative precision of the methods are shown in Table 12, with the 10th centile and
90th centile values. These are consistent with our previous findings indicating that the violation
of joint normality only affects the bias and not the variance.
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Table 9. Operating characteristics (Monte Carlo standard errors in parentheses) of the latent variable,
augmented binary and binary methods when the components of the systemic lupus erythematosus end-
point are drawn from a multivariate skew-normal, N=300 and nsim = 1000
Performance measure Scenario Method
Latent Variable Augmented Binary Binary
MSE skew1 0.039 (0.001) 0.063 (0.003) 0.066 (0.003)
skew2 0.021 (0.001) 0.063 (0.003) 0.065 (0.003)
skew3 0.014 (0.001) 0.060 (0.003) 0.060 (0.003)
skew4 0.010 (0.001) 0.064 (0.004) 0.065 (0.003)
EmpSE skew1 0.097 (0.003) 0.248 (0.006) 0.257 (0.007)
skew2 0.102 (0.002) 0.249 (0.006) 0.254 (0.006)
skew3 0.099 (0.002) 0.241 (0.005) 0.245 (0.006)
skew4 0.094 (0.002) 0.254 (0.006) 0.255 (0.006)
ModSE skew1 0.010 (0.006) 0.052 (0.001) 0.064 (0.001)
skew2 0.010 (0.003) 0.050 (0.001) 0.060 (0.001)
skew3 0.010 (0.015) 0.048 (0.001) 0.059 (0.001)
skew4 0.009 (0.004) 0.051 (0.001) 0.063 (0.001)
Table 10. Estimated probability of response in the treatment and placebo arms from the latent variable
model (Lat Var), augmented binary method (Aug Bin) and standard binary method (Bin) when the
components of the systemic lupus erythematosus endpoint are drawn from a multivariate skew-normal,
N=300 and nsim = 1000
Pr(resp | T = 0) Pr(resp | T = 1)
Scenario True Lat Var Aug Bin Bin True Lat Var Aug Bin Bin
skew1 0.259 0.263 0.221 0.258 0.365 0.330 0.326 0.359
skew2 0.290 0.287 0.253 0.290 0.398 0.370 0.361 0.392
skew3 0.309 0.302 0.271 0.308 0.418 0.394 0.382 0.413
skew4 0.309 0.299 0.269 0.307 0.309 0.292 0.270 0.307
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Table 11. Estimated odds ratio treatment effect from the latent variable model (Lat Var), augmented
binary method (Aug Bin) and standard binary method (Bin) when the components of the systemic lupus
erythematosus endpoint are drawn from a multivariate skew-normal, N=300 and nsim = 1000
Treatment effect
Scenario True Lat Var Aug Bin Bin
skew1 1.640 1.379 (1.140, 1.668) 1.708 (1.093, 2.668) 1.616 (0.985, 2.651)
skew2 1.617 1.459 (1.203, 1.770) 1.676 (1.083, 2.594) 1.586 (0.980, 2.565)
skew3 1.611 1.505 (1.243, 1.822) 1.674 (1.089, 2.572) 1.585 (0.987, 2.548)
skew4 1.000 0.967 (0.807, 1.160) 1.007 (0.647, 1.566) 1.001 (0.613, 1.634)
Table 12. Estimated relative precision from the latent variable model (Lat Var), augmented binary method
(Aug Bin) and standard binary method (Bin) when the components of the systemic lupus erythematosus
endpoint are drawn from a multivariate skew-normal, N=300 and nsim = 1000
Treatment effect
Scenario Lat Var vs Bin Lat Var vs Aug Bin Aug Bin vs Bin
skew1 6.903 [5.336, 8.972] 5.579 [4.376, 7.313] 1.231 [1.189, 1.275]
skew2 6.263 [5.013, 7.917] 5.177 [4.096, 6.518] 1.213 [1.178, 1.252]
skew3 6.326 [5.016, 7.995] 5.192 [4.098, 6.548] 1.219 [1.184, 1.257]
skew4 7.384 [5.729, 9.343] 5.985 [4.655, 7.629] 1.231 [1.192, 1.273]
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Appendix G
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Fig. 11. Plot of the modified Pearson residuals from the latent variable model for each patient in the
MUSE trial. The residuals highlight that two patients observations are poorly explained by the model
but that the model is a good fit for the remaining patients.
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Fig. 12. Histogram of the modified Pearson residuals from the latent variable model in the MUSE trial
dataset with the corresponding χ2 density. The modified Pearson residuals should follow the distribution
of the χ2 density shown if the model fits well.
